M&A Deal Summary

LEO Pharma Acquires Astellas Pharma - Global Dermatology

On November 11, 2015, LEO Pharma acquired life science company Astellas Pharma - Global Dermatology from Astellas Pharma for 675M EUR

Acquisition Highlights
  • This is LEO Pharma’s 1st transaction in the Life Science sector.
  • This is LEO Pharma’s 0th largest (disclosed) transaction.
  • This is LEO Pharma’s 1st transaction in the United States.

M&A Deal Summary
Date 2015-11-11
Target Astellas Pharma - Global Dermatology
Sector Life Science
Buyer(s) LEO Pharma
Sellers(s) Astellas Pharma
Deal Type Divestiture
Deal Value 675M EUR

Target

Astellas Pharma - Global Dermatology

United States
Astellas Pharma - Global Dermatology is a provider of pharmaceutical services.

Search 193,724 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

LEO Pharma

Ballerup, Denmark

website

Category Company
Founded 1908
Sector Life Science
Employees5,045
Revenue 1.4B EUR (2022)
DESCRIPTION

LEO Pharma engages in medical dermatology with a robust R&D pipeline, a wide range of therapies, and a pioneering spirit. LEO Pharma supports people in managing their skin conditions. LEO Pharma was founded in 1908 and is based in Ballerup, Denmark.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (United States) 1 of 1
Year (2015) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-07-21 LEO PDE4 Inhibitor

Ballerup, Denmark

LEO PDE4 Inhibitor compound series has the potential for the treatment of psoriasis and other immune-dermatological disorders.

Sell $200M

Seller(S) 1

SELLER

Astellas Pharma

Tokyo, Japan

website

Category Company
Founded 1923
Sector Life Science
Employees14,522
Revenue 1,296.2B JPY (2022)
DESCRIPTION
Astellas office complex in Northbrook, Illinois.
Astellas office complex in Northbrook, Illinois.

Astellas Pharma is a pharmaceutical company committed to the therapeutic fields of urology, immunology, oncology, neuroscience and DM complications and metabolic diseases. Astellas researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia. Astellas Pharma was incorporated in 1923 and is based in Tokyo, Japan.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 2
Country (United States) 1 of 1
Year (2015) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-05-16 Perseid Therapeutics

Redwood City, California, United States

Perseid Therapeutics LLC engages in the discovery, and research and development.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-10-28 Ganymed Pharmaceuticals AG

Mainz, Germany

Ganymed Pharmaceuticals AG is a biopharmaceutical company developing a new class of immunotherapeutic cancer drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues.

Buy €422M
Mergr

Product

Company

Legal